WebJun 15, 2024 · The oral factor XIa inhibitor asundexian showed a favourable safety profile in a phase 2 study that investigated 755 patients with atrial fibrillation (AF). In addition, lower bleeding rates were reported for patients who were randomised to asundexian than for those who received apixaban. Thus, factor XI is a promising target to prevent thrombosis in … WebWorking your way from 0 to 1500 hours can be accomplished at PFA. Our school was founded by airline pilots and flight instructors, so we know exactly what it takes to achieve …
ESC 22: PACIFIC-AMI: FXIa Inhibitor on Top of DAPT After AMI
WebJan 6, 2024 · Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K … WebPACIFIC-AF. Research type. Research Study. Full title. Multicenter, randomized, active comparator-controlled, double-blind, double-dummy, parallel group, dose-finding Phase 2 study to compare the safety of the oral FXIa inhibitor BAY 2433334 to apixaban in patients with atrial fibrillation. IRAS ID. 272690. Contact name. Gregory Lip. Contact email. robot fire truck
Safety of the oral factor XIa inhibitor asundexian …
WebSep 2, 2024 · The PACIFIC-Stroke trial is a phase 2b dose-finding study designed to assess the safety and potential efficacy of asundexian for prevention of brain infarction, both covert and symptomatic, in patients with acute non-cardioembolic ischaemic stroke. WebThe PACIFIC-AF Study April 05, 2024 Manesh Patel and C. Michael Gibson discuss the results of a phase II trial comparing the safety profiles of asundexian versus apixaban in … WebApr 9, 2024 · Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, … robot fish game